Skip to content

Population-based Brest Stroke Registry

The Brest Registry of Stroke

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02900521
Acronym
BREST
Enrollment
15000
Registered
2016-09-14
Start date
2008-01-31
Completion date
2026-12-31
Last updated
2023-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Hemorrhage, Brain Ischemia, Cerebral (CVAs), Cerebrovascular Disorders, Hemorrhagic Stroke, Ischemic Cerebrovascular Accident, Ischemic Stroke, Stroke, Transient Ischemic Attack (TIA)

Brief summary

The registry is the main objective exhaustive list of cases validated stroke brain on a geographical area defined to calculate an incidence.

Detailed description

The main objective of Brest Stroke Registry is to regroup all confirmed cases of stroke over a defined geographical zone in order to calculate an incidence. There are three prospective medium-term goals: \- In respect with public health epidemiology: 1. To obtain incidence data and evaluate the regional and international divergences 2. To obtain the mortality data in short and long term. Since the onset of the registry, it has been implemented a study on the mortality of stroke patients of Brest Registry. This study has been realized independently for both types of stroke, i.e. ischemic and hemorrhagic, with different caused mortality. This mortality was studied at medium-term (≤ 28 days) as well as at long-term (\> 28 days). There will be a collaboration project between Public Health Surveillance (InVS), Brest University Hospital and Rennes network on all causes of death. 3. Pharmaco-epidemiology In clinical terms, the registry offers an opportunity to do an inventory of all current practices (diagnosis, therapies and the subsidiaries) and propose in this manner the best management of stroke. This strategy is in line with the pilot programs deployed by the French High Health Authority (HAS) for improvement of quality and safety of the health care. The bleeding risk associated with anticoagulants and anti-platelet agents in people of Brest as well as that of Dijon and Lille (in collaboration with their respective registry) will be analyzed. This study has gained a particular characteristic since 2012 with emerging new oral anticoagulants (OAC) which have shown less associated bleeding risks compared with vitamin K antagonists (randomized controlled trials). •In terms of clinical research : 1. Study the impacted consequences of stroke by socio-economic characteristics of the territories in the Pays de Brest 2. Identify short and long term clinical predictors of mortality in patients who have had a hemorrhagic stroke. 3. To identify clinical predictors of mortality in the short and long-term patients with ischemic stroke. 4. To identify genetic predictors of mortality and long-term recurrence of patients with ischemic stroke 5. Identify stroke identification algorithm from existing databases

Interventions

None listed

Sponsors

Santé publique France-InVS (Institut National de Veille sanitaire)
CollaboratorUNKNOWN
Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
University Hospital, Brest
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnostic validated for one of the following pathologies: * Ischemic stroke, * Non-traumatic intracranial hematoma * Cerebral venous thrombosis Diagnostic after December 31, 2007 Age \> 15 years on the date of the diagnostic Patient domiciled at the time of the diagnostic in one of the 79 communes defined beforehand

Exclusion criteria

* Age ≤ 15 years * Validated diagnosis (see below, § 4.2.2) of aneurysmal subarachnoid hemorrhage cerebrovascular * Diagnosis made before 1 January 2008 * Unconfirmed diagnosis * Patient domiciled outside the previously defined area of residence

Design outcomes

Primary

MeasureTime frameDescription
Type of stroke (ischemic or haemorrhagic)InclusionThe type of stroke ischemic or haemorrhagic will be collected from physician diagnostic

Secondary

MeasureTime frameDescription
Patient outcomeEvery year after the inclusion during 10 yearsPatient outcome (mortality) wanted by mail from towns of birth

Countries

France

Contacts

Primary ContactSerge TIMSIT
serge.timsit@chu-brest.fr+33298347620

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026